stem cell final

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/74

encourage image

There's no tags or description

Looks like no tags are added yet.

75 Terms

1
New cards

secretory products from living cells

soluble factors, extracellular vesicles, and membrane-less EVs

2
New cards

soluble factors

proteins, neurotransmitters, metabolites

3
New cards

membrane-less EVs (extracellular vesicles)

exomere, supermeres, condesates, chromatomeres

4
New cards

extracellular vesicles

lipid bilayer bound, exosomes, ectosomes/microvesicles, apoptotic bodies

5
New cards

when are apoptotic bodies usually released?

when cell is dying

6
New cards

ectosomes released by different types of cells are _

called by different names

7
New cards

retinoic acid

can differentiate pluirpotent P19 cells into P19 neurons

8
New cards

PNGaseF

reduces size of amino acids

9
New cards

how is purification of exosomes done?

differential centrifugation

10
New cards

what gene is not in exosomes?

tsg101

11
New cards

CD63

gene on cell surface of exosomes

12
New cards

Dil

dye that labels exosomes

13
New cards

UD-P19 and P19N internalize

P19N exosomes

14
New cards

what can P19 exosomes do?

induce differentiation of UD-P19 to P19 neurons, UD-P19 exosomes will NOT do this

15
New cards

MAP2 antibody

microtubule protein found in post-mitotic neurons

16
New cards

there is differential expression of _ in UD-P19

ncRNAs

17
New cards

folic acid deficiency in fetus

starts with BMP and Wnt signaling pathway, fetus has to be aborted

18
New cards

what are exosomes natural function?

cellular communication

19
New cards

where can exosomes be sourced from?

blood, urine, saliva, cell culture

20
New cards

how can exosomes be engineered?

surface modification to send them to specific areas and content modification to put something inside

21
New cards

why do we need delivery vehicles?

delivery to target site, drug stability, biocompatibility, reduced non-target site toxicity

22
New cards

how small are exosomes?

50-150 nanometers

23
New cards

content loading strategy at parent cell level

genetic engineering, direct co-culture

24
New cards

content loading strategy at EVs level

co-incubation, extrusion, freeze-thaw, electroporation

25
New cards

surface engineering at parental cell level

constant harvest but time consuming

26
New cards

surface engineering EVs level

more simplicity but limited numbers

27
New cards

main synthetic nanoparticle

liposome

28
New cards

pros and cons of natural EVs

biocompatibility and considered as waste for GMP cell production, but batch to batch variation in size, concentration, exact function

29
New cards

liposomes pros vs cons

consistency in production and easy to produce, but lack natural tissue tropism

30
New cards

how can nanoparticles be seen?

TEM, nuclear imaging, fluorscent protein and organic fluorescent dye

31
New cards

degenerative joint disease/osteoarthritis

always secondary in animals with a direct cause

32
New cards

pathophysiology of secondary DJD

altered stress on articular cartilage → chondrocyte damage → proinflammatory mediators → synovial inflammation, thinner joint fluid and cartilage damage → altered stress on articular cartilage

33
New cards

proinflammatory mediators

pro-inflammatory cytokines, proteolytic enzymes, interleukins, prostaglandins, nitric oxide, nerve growth factors

34
New cards

types of DJD treatments

symptomatic, salvage, and SMOADs/DMOADs

35
New cards

symptomatic DJD treatments

physical therapy, nutraceuticals, analgesics, intra-articular analgesia

36
New cards

salvage DJD treatments

joint replacement surgeries, preventative surgery

37
New cards

structure/disease modifying OA drugs

halt/reverse inflammatory cascade and delay/stabilize/reverse cartilage/synovial damage, viscosupplementation, platelet rich plasna, mesenchymal stem cells, and stromal vascular fraction

38
New cards

platelet rich plasma

higher concentration of platelets injected intra-articularly, need to purify blood so only platelets, can have adverse effects, good short-term, but limited long term assesment

39
New cards

mesenchymal stem cells

from bone marrow or fat, takes a while to purify and grow stem cells, injected intra-articularly, but many different risks including oncogenic effects

40
New cards

stromal vascular fraction

has more cellular components, can be done quickly, faster effects than MSC but not sustained

41
New cards

challenges with designing a study

dog variations, using multiple treatments and causing confounding factors, differences in severity of disease between dogs

42
New cards

blood-derived orthobiologics

platelet-rich plasma, autologous conditioned serum, autologous protein solution, alpha-2 macroglobulin

43
New cards

cell/marrow-based orthobiologics

bone marrow aspirate concentrate and MSCs

44
New cards

tissue allografts and emerging orthobiologics

amniotic tissue allograft, extracellular vesicles/secretome products, and lyophilized cell-free preparations

45
New cards

uses and limitations of PRP in horses

intralesional tendonitis and intra-articular OA, no standardized dose or leukocyte concentration

46
New cards

ACS/IRAP

monocytes from horse blood conditioned on glass beads, high IL-1ra, 24 h processing, used for synovitis/OA, multiple doses per kit than can be frozen

47
New cards

APS/pro-stride

concentrate of WBCs, platelets and plasma proteins, high IL-1ra and growth factors, mainly for OA, single dose per kit

48
New cards

alpha-2 macroglobulin

protease inhibitor and cytokine modulator, multiple doses possible, can be frozen, mainly for OA/synovitis

49
New cards

BMAC

centrifugation of patient bone marrow with MSCs, platelets, leukocytes, and high IL-1ra, for OA, cystic lesions, soft tissue injuries, needs to be collected under anesthesia

50
New cards

MSCs horse lesion evidence

for reduced reinjury, not return to work or healing

51
New cards

renovo/aminotic tissue allograft

off the shelf, rich in il-1ra, growth factors, supplements and protects tissues, for tendonitis and soft tissue injuries, limited control trials

52
New cards

extracellular vesicles/secretomes for horses

off the shelf, cell-free, very early stages

53
New cards

tissue engineered heart valves

for children so that they can grow with the child, can come from valve endothelial cells, valve interstitial cells, mesenchymal stem cells, or mononuclear cells

54
New cards

what heart valve is most affected with children?

aortic/pulmonary semilunar valves

55
New cards

what does anisotropic mean?

heart valves have different properties and forms depending on the direction

56
New cards

mechanical valve substitutes

excellent durability and function, but require lifelong anticoagulation therapy

57
New cards

bioprosthetic valve substitutes

good durability and function, but may require anticoagulation therapy for a period, and prone to calcification

58
New cards

homograft substitute

good durability, function, and surgical flexibility, but may calcify

59
New cards

scaffold

will be decellularized or polymer, maintains shape and mechanical support as tissue develops

60
New cards

decellularized heart valve

removal of cells, DNA, and GAGs, will still have most of ECM, collagen, elastin, and basement membrane

61
New cards

four steps of evaluating valve performance

component mechanical behavior → composition analysis → intact valve performance → and large animal models

62
New cards

planar biaxial testing

pull from all four sides, decellularization has significant stretch and arial strain due to space from cell removal

63
New cards

stress relaxation

measure of the time dependent response of the leaflet, shows how leaflet handles sustained load, significant reduction in decellularization

64
New cards

in vivo valve performance

in 20-week sheep juvenile model to mainly show calcification largely decreased in decellularization

65
New cards

pulsatile conditioning

will cause cells to migrate into other parts of tissue

66
New cards

cancer

an umbrella term for a large and diverse group of over 100 diseases

67
New cards

cancer core mechanism

has uncontrolled growth, no maturation, and cell death processes are lost

68
New cards

why is cancer a stem cell disease?

stem cells will acquire changes in cancer that disregulate their processes and may escape their niche

69
New cards

benign tumor vs malignant

benign grow more slowly and do not metastatasize, while malignant tumors do

70
New cards

first line cancer treatments

surgery, radiation, immunotherapy, chemotherapy, targeted therapies, and hormone therapy

71
New cards

lymphoma

blood cell tumor featuring B or T cell lymphocytes, tell which one with flow cytometry markers

72
New cards

R-CHOP

first line treatment for B-cell cancer, cures 50-70%, mainly targets DNA

73
New cards

CAR-T

engineered T cells that target B-cell lymphoma with lentivirus, used as a second-line/rescue treatment, main adverse events are CRS and ICANS

74
New cards

melanoma

solid tumor from melanocytes, abnormal pigemented mole/skin patch, first line treatments are anti PD-1 and MEK inhibitors, second line treatment is TIL

75
New cards

TIL

obtain and grow tumor-reactive TILs from body, infuse with IL-2s into patient to kill tumor